- AU$1.71bn
- AU$1.67bn
- AU$5.85m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 295.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -127.1% | ||
| Return on Equity | -1049.2% | ||
| Operating Margin | -2841.17% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.22 | 1.05 | 0.72 | 3.75 | 5.85 | 8.53 | 24.73 | 36.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
4DMedical Limited is a medical technology company that creates and deploys software-based cardiothoracic imaging technology integrating both algorithms and artificial intelligence. The Company's software platform delivers quantitative insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease. It provides thoracic imaging that enhances physician diagnoses and management of respiratory conditions. Its products include CT:VQ-Non-Contrast Ventilation-Perfusion, CAC-Coronary Artery Calcification, CT LVAS-Lung Ventilation Analysis, IQ-UIP-Early IPF Detection, LDAf-Functional Lung Density Analysis, LDAi-Lung Density Analysis – Inspiration, LTA-Lung Texture Analysis, PHA-Pulmonary Hypertension Assessment, XV LVAS-Lung Ventilation Analysis, and Companion Imaging. The CT:VQ is a non-contrast post-processing technology that transforms routine, chest computed tomographies (CTs) into quantitative, lobar ventilation (V) and perfusion (Q) maps.
Directors
- Bruce Rathie NEC (61)
- Andreas Fouras CEO
- Heath Lee CFO
- Charlene Stahr SEC
- John Livingston NED
- Julian Sutton NED
- Lilian Bianchi NID
- Evonne Collier NID
- Robert Figlin NID
- Last Annual
- June 30th, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- December 17th, 2012
- Public Since
- August 7th, 2020
- No. of Shareholders
- 13,115
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 534,167,121
- Address
- Level 7/700 Swanston Street, Carlton, MELBOURNE, 3053
- Web
- https://4dmedical.com/
- Phone
- +61 395455940
- Contact
- Simon Hinsley
- Auditors
- PKF Melbourne Audit & Assurance Pty Ltd
Upcoming Events for 4DX
4DMedical Ltd Annual Shareholders Meeting
Similar to 4DX
Adheris Health
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
Atomo Diagnostics
Australian Stock Exchange - SEATS
FAQ
What is the 4DMedical share price?
As of Today at 19:01 UTC, shares in 4DMedical are trading at AU$3.21. This share price information is delayed by 15 minutes.
How has the 4DMedical share price performed this year?
Shares in 4DMedical last closed at AU$3.21 and the price had moved by +988.14% over the past 365 days. In terms of relative price strength the 4DMedical share price has outperformed the ASX All Ordinaries Index by +920.43% over the past year.
What are the analyst and broker recommendations for 4DMedical?
The overall consensus recommendation for 4DMedical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the 4DMedical dividend yield?
4DMedical does not currently pay a dividend.
Does 4DMedical pay a dividend?
4DMedical does not currently pay a dividend.
When does 4DMedical next pay dividends?
4DMedical does not currently pay a dividend.
How do I buy 4DMedical shares?
To buy shares in 4DMedical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 4DMedical?
As of the previous close price of AU$3.21, shares in 4DMedical had a market capitalisation of AU$1.71bn.
Where are 4DMedical shares listed?
Here are the trading details for 4DMedical:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: 4DX
What kind of share is 4DMedical?
Based on an overall assessment of its quality, value and momentum 4DMedical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 4DMedical share price forecast for 2026?
The analyst consensus target price for shares in 4DMedical is AU$4.53. That is 41.21% above the last closing price of AU$3.21.
Analysts covering 4DMedical currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.05 for the next financial year.
Find out moreWhat is the trend in the 4DMedical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4DMedical. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +126.9%.
As of the last closing price of AU$3.21, shares in 4DMedical were trading +13.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 4DMedical PE Ratio?
The 4DMedical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$3.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 4DMedical?
4DMedical's management team is headed by:
- Bruce Rathie - NEC
- Andreas Fouras - CEO
- Heath Lee - CFO
- Charlene Stahr - SEC
- John Livingston - NED
- Julian Sutton - NED
- Lilian Bianchi - NID
- Evonne Collier - NID
- Robert Figlin - NID